GlassScriptPhysician profile
Jordan K Taillon
NPI 1790081701
$8,654.80
in general payments reported to CMS, 2019-2025
28 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $341 · 2021: $196 · 2022: $372 · 2023: $4,482 · 2024: $428 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,020 · Travel and Lodging: $1,988 · Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,020.00 |
| Travel and Lodging | $1,988.35 |
| Food and Beverage | $1,332.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,576.88 | 2023-2025 | Ion, Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $768.48 | 2019-2025 | Fasenra, Andexxa |
| Actelion Pharmaceuticals US, INC. | $475.83 | 2019-2021 | |
| Glaxosmithkline, LLC. | $312.63 | 2019-2024 | Nucala |
| Allergan, INC. | $240.27 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.53 | 2019-2020 | |
| Abbvie INC. | $159.42 | 2021-2024 | Avycaz |
| Janssen Pharmaceuticals, INC | $105.58 | 2019-2023 | Xarelto |
| Pfizer INC. | $91.94 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $75.73 | 2019 | |
| Csl Behring | $68.99 | 2023-2025 | Kcentra |
| Mylan Specialty L.P. | $67.90 | 2019 | |
| Pentax of America, INC. | $53.21 | 2022 | |
| Mallinckrodt Hospital Products INC. | $50.33 | 2020 | |
| Shire North American Group INC | $47.75 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $40.17 | 2019-2024 | Giapreza |
| Philips North America LLC | $39.89 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.30 | 2019 | |
| United Therapeutics Corporation | $36.66 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.99 | 2019-2020 | |
| Chiesi USA, INC. | $34.85 | 2020-2022 | |
| Grifols USA, LLC | $19.60 | 2019 | |
| Genzyme Corporation | $19.42 | 2019 | |
| Inari Medical, INC. | $19.10 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Insmed, INC. | $17.58 | 2019 | |
| Electromed, INC. | $16.91 | 2019 | |
| Baxter Healthcare | $16.63 | 2023 | Starling System |
| Sunovion Pharmaceuticals INC. | $15.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Taillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.